The development and evaluation of new combination vaccines is an important public health endeavor. Trials to evaluate these vaccines are customarily designed and analyzed as noninferiority studies. We explain the concept of noninferiority and highlight important issues that can be challenging in the statistical evaluation of these vaccines. Topics covered include end points, hypotheses, and analyses for comparing geometric mean concentrations (or titers) of antibody and proportion of vaccine recipients responding; covariate adjustment; the problem of multiplicity and its impact on sample size; and choice of a meaningful difference to rule out.
into a single-injection vaccine should not produce a product that is inferior with respect to any of its individual components. Clearly, the concern is one-directional because there is no concern about whether the combination vaccine is superior to the separately administered components.
Such a goal fits naturally into the design of noninferiority trials [2] . These studies are 1-sided equivalence trials, which are mentioned in the US Food and Drug Administration Center for Biologics Evaluation and Research combination vaccine guidance document [3] . The goal of a noninferiority trial is to demonstrate that an investigational product is not inferior to a control product (usually an active product for the same disease indication) by a clinically important amount, with respect to the chosen end points.
EFFICACY END POINTS
Efficacy end points in combination vaccine studies are usually not cases of an infectious disease, especially if the components are already licensed or their efficacy has been previously demonstrated [4] . Instead, measures of immune response are used as correlates of protection, and efficacy is inferred from these measures. Unfortunately, these immune response end points are not as easily understood as clinical end points.
Two immune response end points are commonly used for primary efficacy evaluation. One is geometric Downloaded from https://academic.oup.com/cid/article-abstract/33/Supplement_4/S306/301887 by guest on 24 November 2018 mean concentration (GMC) or geometric mean titer (GMT) of antibody. The other is the proportion of vaccine recipients who respond in a prescribed manner. This latter end point is especially meaningful if there is a particular threshold level of immune response that is believed to be important. For example, for Haemophilus influenzae type b (Hib), proportions of recipients with a postvaccination concentration of anti-polyribosyl ribitol phosphate antibody that is у0.15 mg/mL and у1.00 mg/ mL have been used to evaluate the immune response to the Hib component.
The above end points are the most common ones used for primary evaluation, perhaps because they are readily amenable to hypothesis testing and are easily understood conceptually. Often, one of these end points may be specified as primary, with the other as the secondary end point for efficacy. However, especially when there is no established correlate of protection for a particular vaccine component, it may be difficult to infer anything regarding one end point without consideration of the other.
There are also other ways of evaluating immune response data, summarized elsewhere [5, 6] . Some of these approaches are often used for secondary, supportive assessments of the data to accompany the primary analysis end points already mentioned. However, many of these methods, particularly the graphical ones, tend not to lend themselves readily to hypothesis testing, especially testing of noninferiority. Therefore their role is usually viewed as supportive and exploratory, rather than primary.
HYPOTHESES
Hypotheses are easily specified once the primary end point has been chosen. It is advisable to begin with the alternative hypothesis, which is what the trial aims to demonstrate with respect to the primary end point. In a combination vaccine noninferiority trial, the alternative hypothesis is that the combination vaccine is not inferior to the separate components, by a specified amount. Because of biological variability, as well as other sources of variability, it is not possible to show that 2 vaccines are exactly equal, but it can be shown that they are likely similar within a specified margin that is, ideally, clinically meaningful.
When the alternative hypothesis has been determined, the null hypothesis follows immediately: it is just the complement of the alternative. For a combination vaccine, the null hypothesis is that the combination is inferior by a specified amount. The combination vaccine trial is then designed to reject (not demonstrate) the null hypothesis. This statement is a key point; it means that the conventional null hypothesis of no difference is not appropriate for the aim of a noninferiority/similarity trial. That is, if the goal is to show that 2 vaccines are similar (in this case, one is noninferior to the other), then this similarity (noninferiority) must be expressed as the alternative hypothesis rather than the null hypothesis.
ERROR PROBABILITIES
A common but mistaken perception is that when an equivalence or noninferiority trial is conducted, the error probabilities, type 1 and type 2, are interchanged. This notion is not correct. If a trial is appropriately designed to demonstrate the alternative hypothesis and reject the null, the error probabilities have their usual meaning.
The type 1 error probability, denoted by a, is the probability of rejecting the null hypothesis when it is true (should not be rejected). In a combination vaccine trial, it is the probability of claiming that the combination vaccine is similar (not inferior) to the separately administered components when it is indeed inferior by a specified amount. The type 2 error probability, denoted by b, is the probability of not rejecting the null hypothesis when it is false (should be rejected). For a combination vaccine trial, it is the probability of not concluding that the combination vaccine is similar (noninferior) to the control when it really is similar (noninferior), within a specified range. Further explanation of error probabilities and combination vaccine trials can be found in the proceedings of the 1993 conference on Combined Vaccines and Simultaneous Administration [7] .
GMC: HYPOTHESES
Assume that the GMC of antibody has been chosen as the primary end point for a combination vaccine trial (the same approach is taken for GMT). The next step is to specify the hypotheses. For clarity, they are expressed here first in words because that is how clinicians are most likely to think of them. Because concentrations or titers are often approximately lognormally distributed, they are customarily analyzed on a logarithmic (log) scale; a difference in arithmetic means on a log scale becomes a ratio of geometric means when the results of analysis are converted back to the original data scale. Thus, each hypothesis is a statement regarding a ratio of geometric means. Again, it is advisable to start with the alternative hypothesis because that is what the trial is designed to demonstrate. The alternative hypothesis for each vaccine component can be written in words as follows:
(1) Alternative hypothesis. The ratio of the GMC of antibody in the combination vaccine group to the GMC in the control (separate component) group is greater than a threshold value, ideally a clinically important amount.
It is important also to write hypotheses with the precision of meaning that the language of mathematics provides. Thus, a statistical version of hypothesis 1 is given as follows:
where v is the target population parameter we wish to make an inference about (in this case, the ratio of geometric means), m combination and m separate are the target population GMCs of antibody for those receiving the combination and separately administered vaccine components, respectively, and v 0 is the specific threshold value hypothesized for the ratio of GMCs. That is, v is the population parameter targeted for inference, and v 0 is a specific numerical value of it assumed under the null hypothesis (thus the 0 subscript).
Testing for noninferiority implies that we want the trial to rule out the finding that the immune response in the combination vaccine group is too much below that in the control group. When the mean response in the combination vaccine group is lower than that in the control group, the ratio of GMCs of antibody, as stated in the equation for alternative hypothesis 1, will be a decimal fraction !1. The immune response to the combination vaccine will be allowed to drop a little (and still consider the combination to be clinically not inferior to the separately administered component), as long as it does not drop too much. Indeed, such a result would not be inconsistent with the mean responses truly being the same. Thus, a threshold value, for example 0.50, is specified as being the value above which the ratio of mean concentrations of antibody must be (thus the phrase "greater than" in the alternative hypothesis) in order for noninferiority to be claimed for the combination vaccine.
The null hypothesis, which those performing the clinical trial hope will be rejected, follows immediately from the alternative hypothesis. It is the complement of the alternative specification and can be written in words as follows:
(2) Null hypothesis. The ratio of the GMC of antibody in the combination vaccine group to the GMC in the control (separate component) group is equal to or less than a threshold value, ideally a clinically important amount.
The null hypothesis can be written statistically as follows:
where quantities are as defined above for the equation for hypothesis 1. Note that hypothesis 2 is not the conventional null hypothesis that the ratio is equal to 1, which is a consequence of designing the trial to establish noninferiority rather than demonstrate superiority (or detect a difference). If the null hypothesis cannot be rejected, it will signify that the immune response to the combination vaccine component may have dropped too low, according to the previously specified threshold criterion (0.50, in this example). Or it could mean that the sample size was not sufficient to reject the null hypothesis-so it is important that the sample size for the trial be large enough to provide adequate power to reject the null hypothesis, if the alternative hypothesis is indeed true.
GMC (OR GMT): ANALYSIS
Because the above hypotheses are statements regarding a ratio, the analysis must reveal information about the specified ratio; otherwise, the analysis will not be useful for testing the hypothesis. A simple and appropriate method of analysis is to determine a CI. A 2-sided 1-2a CI allows a noninferiority test of size a (i.e., the probability that a type 1 error, of wrongly claiming noninferiority, is at most a, not 2a). For example, if we use a 2-sided 90% CI, then the type 1 error probability will not exceed 0.05.
Illustrative results for the ratio of GMCs from a noninferiority study of a combination vaccine could be as follows: , v 0.80; 1-2a CI, 0.62-1.01. labels the estimated ratio of GMCŝ v calculated from the study; this point estimate is our best guess of v, the target population ratio of GMCs that we wish to estimate. In this case it is 0.80. The corresponding 1-2a CI indicates that the true value of v is likely to be somewhere between 0.62 and 1.01.
Because the equations for hypotheses 1 and 2 express the combination vaccine mean response in the numerator of the ratio and the control mean in the denominator, we evaluate the data by the lower limit of the above CI. According to the equation for hypothesis 1, we consider whether or not the lower limit exceeds v 0 , which is 0.50 in this example. Because the lower limit, 0.62, is greater than 0.50, we reject the null hypothesis and conclude the alternative: the combination is not inferior to the control by the specified amount. Thus, the trial has achieved its aim. Had we chosen v 0 to be 0.67, then we could not claim noninferiority with respect to this previously specified criterion, because the lower confidence limit, 0.62, does not exceed 0.67.
As mentioned, the preceding interpretation comes about because the numerator and denominator of the ratio were defined as above. However, it should be noted that if the GMC for the combination vaccine had been in the denominator rather than the numerator, we would consider only the upper confidence limit, specify v 0 as 2.00 instead of 0.50, and change the direction of the inequality signs in the hypotheses. Thus, if the reader should encounter the evaluation presented in this manner, he or she can be assured that it is correct. The 2 specifications are equivalent, and which is chosen depends only on the analyst's preference.
PROPORTIONS OF RECIPIENTS RESPONDING: HYPOTHESES
Again, hypotheses for each vaccine component can be written in words as follows:
(3) Alternative hypothesis. The proportion responding among combination vaccine recipients minus the pro-portion responding among control vaccine recipients (the difference in proportions of recipients responding) is greater than a threshold value, ideally a clinically important amount.
This alternative hypothesis can be written statistically as follows:
where d is the target population parameter we wish to make the inference about (in this case, a difference in proportions responding), P combination and P separate are the target population proportions responding for those receiving the combination and separately administered vaccine components, respectively, and d 0 is the specified threshold for the difference in proportions.
The logic for evaluation is similar to that used to analyze GMCs of antibody: to provide evidence of noninferiority, trial results should rule out the finding that the proportion of recipients responding to the combination vaccine is substantially less than the proportion responding to the control vaccine. When the proportion of recipients responding to the combination vaccine is lower than that for the control vaccine, the difference between the 2 proportions, as defined in the equation for hypothesis 3, will be a negative decimal fraction (when they are the same, the difference will be zero). Therefore, a threshold value, for example Ϫ0.10, might be specified as being the value above which the difference in proportions of recipients responding must be in order for the combination vaccine to be considered not inferior to the control vaccine.
Again, the null hypothesis (which the trial is designed to reject) follows immediately as the complement of the alternative specification. It can be written in words as follows: (4) Null hypothesis. The proportion responding among combination vaccine recipients minus the proportion responding among control vaccine recipients (the difference in proportions of recipients responding) is equal to or less than a threshold value, ideally a clinically important amount.
This null hypothesis can be written statistically as follows: where quantities are defined as for the equation of hypothesis 3. Note that hypothesis 4 is not the conventional null hypothesis of no difference, because the goal is to establish noninferiority rather than superiority (or to detect a difference). If the null hypothesis cannot be rejected, it will suggest that the proportion of recipients responding to the combination vaccine component may have dropped too low, according to the previously specified threshold criterion (Ϫ0.10, in this example). Or, as before, it could mean that the sample size was not sufficient to reject the null hypothesis, if the alternative hypothesis is in fact true (which would mean we had made a type 2 error).
PROPORTION OF RECIPIENTS RESPONDING: ANALYSIS
Note that hypothesis 4 is a statement regarding a difference between 2 proportions. Consequently, the analysis must reveal information about a difference between the 2 proportions in order for it to be useful for testing the hypothesis. Recall that d is the target population difference in proportions of recipients responding that is to be estimated. As for GMCs or GMTs of antibody, the analysis approach for comparing proportions of recipients responding is a CI.
Illustrative estimates of d from a noninferiority study of a combination vaccine could be as follows: , 0.01; 1-2a CI, d 0.08-0.10. The point estimate of d, calculated from the data, is 0.01 ( ). The corresponding 1-2a CI suggests that the truê d difference in proportions of recipients responding (the true value of d) is likely to be somewhere between Ϫ0.08 and 0.10.
Because the equations for hypotheses 3 and 4 express the difference in proportions of recipients responding by subtracting the proportion of subjects who received separate injections from the proportion who received the combination vaccine, evaluation is based on the lower limit of the above CI. According to the alternative hypothesis 3, we consider whether or not the lower limit of the CI exceeds d 0 , which is Ϫ0.10 in this example. Because the lower limit, Ϫ0.08, is greater than Ϫ0.10, we reject the null hypothesis and conclude the alternative: the proportion of recipients who responded to combination vaccination is not inferior to the proportion who responded to separate injections, by the specified amount. In this case, the trial has achieved its goal. Had we chosen d 0 to be Ϫ0.05, then we would not conclude noninferiority with respect to this previously specified criterion, because the lower confidence limit, Ϫ0.08, is not greater than Ϫ0.05.
As was pointed out with respect to GMCs or GMTs of antibody, an alternative specification of hypotheses is possible here, with the appropriate change in the interpretation of analysis results. If the proportion responding in the combination vaccine group had been subtracted from the proportion responding in the separate-injection group, rather than as specified in the preceding paragraph, then evaluation would be based on the upper confidence limit instead of the lower, with , and the inequality signs in the hypotheses reversed.
Either approach is correct because they are equivalent.
COVARIATES
Scientists often wish to evaluate data while adjusting for 1 or more variables they believe influence the end point of interest. These prognostic variables, often called covariates, are variables measured at baseline-that is, before randomization and medical intervention-so that they cannot be influenced themselves by the intervention administered in the trial. Thus, they cannot be "intermediate" variables in the causal path between the medical intervention and the outcome of interest.
Calculation of CIs can accommodate adjustment for covariates. Regression models may be used to compare immune response to the combination vaccine and the control (i.e., the separately administered components) while adjusting for 1 or more covariates in the model. If a continuous covariate is adjusted for, such as baseline concentration or titer of antibody level, then the analysis is called "analysis of covariance." For example, for GMCs or GMTs, CIs based on least squares means (means that would be expected if the trial had equal numbers of participants assigned to each vaccine group, with all covariates held at their mean value) can be obtained as output from the analysis. CIs obtained in this manner are said to be "conditional" because they are conditioned on the covariates held at their mean levels. Accompanying unadjusted (unconditional) CIs are also informative and should be computed as well.
For confirmatory analyses-that is, analyses that are inferential rather than exploratory in nature-there are compelling arguments that selection of covariates should be done prospectively and should be based on clinical and biological knowledge of the prognostic value of the covariates rather than on significance tests of baseline imbalance [8] . These arguments suggest that the fundamental reason for adjusting for a covariate is because it is a predictor of the outcome, not because it may be unevenly distributed across study groups. For instance, if a baseline covariate is highly correlated with the end point of interest, the covariate may need to be adjusted for even if it is not significantly imbalanced. On the other hand, if a baseline covariate is not associated with the outcome variable, there is nothing gained by adjusting for the covariate even if imbalanced; indeed, such unnecessary control may reduce precision of the estimate of vaccine effect or even admit bias into the estimate [9] .
MULTIPLICITY
When multiple vaccine components are evaluated for a combination vaccine, the problems associated with multiple comparisons are encountered. Usually, multiple evaluations cause inflation of the type 1 error probability. Recall that the Code of Federal Regulations [1] suggests that each component of a combination vaccine should be noninferior to the corresponding separate component for the combination vaccine to be considered noninferior. When "success" must be achieved for each individual end point in order for success to be claimed overall, the statistical theory of "intersection-union" tests applies [10] . This theory simply says that each vaccine component can be evaluated at the a level of significance and the overall type 1 error probability for the combination vaccine as a whole will not exceed a. In other words, there is no need to worry about type 1 error inflation due to the multiple tests. The explanation of why this result is true and how the intersectionunion principle applies is beyond the scope of this article. The purpose in mentioning it here is to assure the reader that the practice of not adjusting a in this situation is solidly grounded in statistical theory.
Unfortunately, however, although the type 1 error probability is controlled, the type 2 error probability (i.e., the probability of failing to conclude noninferiority when the vaccine is truly noninferior) is not. Indeed, power ( type 2 error prob-1 Ϫ the ability) declines as the number of vaccine components evaluated increases. For example, if immune responses to the different components (and therefore the tests) are independent, and each component of a 2-component vaccine is evaluated with power of 0.90, then the evaluation of the vaccine will have overall power of only
. If the vaccine has 3 components, 2 (0.9) p 0.81 the overall power will decline to , and so on. Of 3 (0.9) p 0.73 course, the evaluations of different components may have variable levels of power, but the concept is the same: overall power declines as the number of independent evaluations increases. Therefore, to maintain overall power at a reasonable level, the power for each individual component's test should be increased. Table 1 shows the sample sizes needed to maintain an overall power of 0.80 for comparing proportions of recipients responding, according to the number of vaccine components. The clinically meaningful difference to be ruled out is Ϫ0.10, and the true proportion of recipients responding in both the combination vaccine group and the separate-component group is assumed to be 0.90. The immune responses to the different vaccine components are assumed to be independent, which is a worst-case scenario, in that it requires the largest sample sizes. It can be seen from table 1 that, for 10 components, the individual power needed to maintain overall power of 0.80 is ∼0.98, and for 20 components, it is ∼0.99. The required total sample size (i.e., for both vaccine groups together) for 10 com- ponents is ∼500, and it approaches 600 for 20 components. Such sample sizes would not be considered large-indeed, would be relatively small-for a vaccine efficacy trial with clinical end points. However, for a trial based on immune response end points whose measurement depends on numerous serologic specimens and assays, these sample sizes are quite large.
Various factors influence the required sample sizes in this setting. If immune responses to different vaccine components are correlated and a method is used that accounts for this correlation, required sample sizes may be reduced. Research on methods to account for correlated tests is an area that might be fruitful in yielding a more efficient way to evaluate combination vaccines. Referring again to table 1, if the true proportion of recipients responding to any combination vaccine component is less than 0.90, then the required sample sizes increase. Also, there may be a biological or clinical basis for manipulating d 0 , the clinically relevant difference to be ruled out; a larger d 0 would require smaller sample sizes than those shown.
CHOICE OF v 0 OR d 0
Choosing the value of v 0 or d 0 , the clinically important relative effect to be ruled out, is one of the most difficult decisions necessary in planning noninferiority or equivalence trials. This difficulty is amplified when the clinical relevance of the end point, such as immune response, is not as lucid as that of clinical end points, such as cases of disease. Unless a quantitative correlate of protection is known for a certain vaccine component, it is difficult to discern what difference or decline in immune response is associated with an important increase in disease risk.
It may also be appropriate to consider whether v 0 or d 0 should be assigned a different value for different components (or disease indications) of a combination vaccine. Likewise, should the specifications differ by target population? For example, for severe or debilitating diseases or high-risk populations, should the clinically meaningful relative effects to be ruled out be smaller than for other, less serious indications?
Another concept that warrants consideration in choosing v 0 or d 0 is the phenomenon of "immunogenicity creep." As figure 1 illustrates, it is possible that, if each successive combination vaccine is allowed to decline in immune response by no more than d 0 (an absolute difference in proportions responding of 0.10 in this example) relative to the previous vaccine, the eventual result could be a combination vaccine that is considerably less immunogenic (by much more than a decline of 0.10) than the original vaccine. The potential for this downward creep in immunogenicity should be considered when deciding the general criteria for evaluating an investigational product. Considerations involving the original separate components (if available), an earlier combination vaccine, or a reliable historical standard may be useful in this regard.
If a correlate of protection is known, especially a quantitative one, then choosing a clinically meaningful v 0 or d 0 is facilitated to some extent. Consequently, it is clear that determining-and especially understanding-immune correlates of protection is a critical need when assessing combination vaccines. We hope that continued statistical and biological research in this area will contribute in important ways to combination vaccine evaluation.
